RxDoctor Payments Data

Yafa Minazad, DO

Neurology · Pasadena, CANPI 1982636122

Payments from drug & device makers

$23,782in general payments, 2019–2025

Across 379 payments — averaging $62.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$13K
  • UCB, Inc.$3K
  • AbbVie$2K
  • Covidien LP$556
  • SK Life Science, Inc.$525
  • Medtronic$464
  • plus $5K from 50 others

What the payments were for

  • Consulting fees$5,49023%
  • Speaking & faculty fees$7,58232%
  • Travel & lodging$5052%
  • Food & beverage$10,19343%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,782 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$191,617
Medicare patients
509
Services billed
2,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GlatopaGlatiramer Acetate13$19,299
UbrelvyUbrogepant11$15,504
QuliptaAtogepant11$11,583
Lacosamide26$4,038
Levetiracetam45$2,170
Lamotrigine ErLamotrigine15$2,162
Oxcarbazepine28$1,768
Donepezil Hcl24$1,068
Amitriptyline Hcl33$658
Escitalopram Oxalate52$646
Gabapentin27$575
Lamotrigine37$553
Valproic AcidValproic Acid (As Sodium Salt)16$469
Divalproex Sodium13$75
Lorazepam15$21

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,519$27,08722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.

Other neurology in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →